Simcere Pharmaceutical Group released very positive unaudited financial results for its third quarter. At the same time, the company said it would begin a $50 million share buyback. At the end of the quarter, Simcere reported cash and short-term investments of 831 million RMB ($122.4 million). Simcere produces branded generic pharmaceuticals and its proprietary cancer drug, Endu. More details...
Stock Symbol: (NYSE: SCR)